洛伐他汀
Lovastatin;[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2,;4-hydroxy-6-oxo-2h-pyran-2-yl)ethyl)-1-naphthalenylester,(1s-(1-alpha-(r*),3;4-hydroxy-6-oxo-2h-pyran-2-yl]ethyl]-1-naphthalenyl(s)-2-methyl-butyrate;8-[2-(4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydro-1-naphthale;Mevinolin;MEVINOLIN(AS);DL-Lactic acid;LOVALIP;LOVASTIN;MEVACOR;mevlor;msd803;Paschol;Rovacor;Sivlor;6α-Methylcompactin;Monacolin K;1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl 2-methylbutanoate;洛伐他汀;Lovalord;Mevinacor;Altoprev;Nergadan;Artein;Altocor;6alpha-Methylcompactin;Hipovastin;Lovastatine;Lovasterol;Lipivas;Closterol;Teroltrat;Tecnolip;Cholestra;Rodatin;Lozutin;Lipofren;Lestatin;Hipolip;Colevix;Taucor;Lipdip;Belvas;Lovastatine [French];Lovastatinum [Latin];Lovastatina [Spanish];6-alpha-Methylcompactin;Lovastatinum;Lovastatina;MSD 803;MK 803;6 alpha-Methylcompactin;KBio3_002848;LOVASTATIN [INN];NINDS_001032;UNII-9LHU78OQFD;NSC779704;74133-25-8;BRD-K09416995-001-06-8;HMS2096H13;HMS3676H19;mevinolin;HMS1923O13;NCGC00023509-07;SMR000673570;Lovastatin [USAN:USP:INN:BAN];LOVASTATIN [USP MONOGRAPH];LOVASTATIN [WHO-DD];Pharmakon1600-01503977;KS-1082;Tox21_110888_1;Lovastatin for peak identification;Lovastatinum (Latin);Lovastatin,(S);Prestwick3_000516;BPBio1_000519;HY-N0504;NCGC00023509-10;Simvastatin impurity, lovastatin-;(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-8-(2-((4R,6R)-4-hydroxy-2-oxo-2H-pyran-6-yl)ethyl)-3,7-dimethylnaphtyl(S)-2-methylbutyrat;LOVASTATIN [MI];HMS1990O07;AB00052400_18;MLS001055358;BDBM34168;BRD-K09416995-001-21-7;NCGC00023509-14;CHEBI:40303;Rextat;A838383;MK-803;LOVASTATIN (USP MONOGRAPH);Mevacor;Monacolin K;mevinolin;6-alpha-Methylcompactin;MFCD00072164;(S)-2-Methylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one;(S)-2-Methylbutyric acid, 8-ester with (4R,6R)-6-[2-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one;C07074;NCGC00023509-03;6.alpha.-Methylcompactin;HY-N0504R;PCZOHLXUXFIOCF-BXMDZJJMSA-N;NSC-779704;LOVASTATIN [EP MONOGRAPH];CS-0694830;GTPL2739;L0214;BSPBio_001265;(2S)-(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl-2-methyl butanoate;Lovalip;BIDD:PXR0113;EN300-52515;LOVASTATIN (EP MONOGRAPH);Tox21_201475;BUTANOIC ACID, 2-METHYL-, 1,2,3,7,8,8A-HEXAHYDRO-3,7-DIMETHYL-8-(2-(TETRAHYDRO-4-HYDROXY-6-OXO-2H-PYRAN-2-YL)ETHYL)-1-NAPHTHALENYL ESTER, (1S-(1.ALPHA.(R*),3.ALPHA.,7.BETA.,8.BETA.(2S*,4S*),8.ALPHA..BETA.))-;(2S)-2-methylbutanoic acid [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-2-oxanyl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-y...